DUBLIN, Ireland, May 27, 2026
Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in the New England Journal of Medicine (NEJM), further validating the clinical benefit of Ziihera® (zanidatamab-hrii) in combination-based treatment regimens for patients with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The publication highlights durable and consistent survival outcomes achieved with zanidatamab-containing combinations in the first-line treatment setting and reinforces the therapy’s potential to redefine standards of care for one of the most challenging gastrointestinal cancers. The study findings demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared with the current trastuzumab-based standard of care, providing strong evidence supporting broader clinical adoption and future regulatory expansion.
Phase 3 HERIZON-GEA-01 Delivers Significant Survival Advantage
The global HERIZON-GEA-01 Phase 3 trial enrolled 914 patients across more than 30 countries, making it one of the largest studies conducted in HER2-positive gastroesophageal adenocarcinoma. The trial evaluated zanidatamab plus chemotherapy, with and without the PD-1 inhibitor tislelizumab, against standard treatment consisting of trastuzumab plus chemotherapy. The study focused on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastric, gastroesophageal junction, and esophageal adenocarcinomas.
Results demonstrated that both zanidatamab-containing treatment arms significantly improved progression-free survival compared with standard therapy. Median PFS reached 12.4 months with zanidatamab-based combinations compared with 8.1 months in the trastuzumab control arm. Importantly, the combination of zanidatamab, tislelizumab, and chemotherapy achieved a statistically significant overall survival benefit, extending median OS to 26.4 months versus 19.2 months with standard treatment.
The findings represent one of the most compelling survival improvements reported in first-line HER2-positive gastroesophageal cancer and further strengthen the clinical profile of zanidatamab as a next-generation HER2-targeted therapy. Expanded analyses published in NEJM confirmed that the survival advantages remained consistent across multiple patient populations, geographic regions, and clinical characteristics.
Advertisement
Durable Benefits Observed Across PD-L1 Positive and Negative Patients
One of the most notable aspects of the HERIZON-GEA-01 study was the consistency of benefit observed regardless of PD-L1 expression status. Historically, patients with PD-L1-negative tumors have shown limited responsiveness to immunotherapy-based approaches. However, updated analyses scheduled for presentation at the 2026 ASCO Annual Meeting demonstrated meaningful improvements in both progression-free survival and overall survival among patients receiving zanidatamab-containing regimens regardless of PD-L1 status.
Among patients with PD-L1-negative tumors, median overall survival reached 29.7 months in the zanidatamab, tislelizumab, and chemotherapy group compared with 15.8 months in the control arm. Similarly, patients with PD-L1-positive disease experienced substantial survival improvements, achieving median overall survival of 26.4 months versus 21.2 months with standard treatment.
Researchers believe these outcomes may be linked to zanidatamab’s unique bispecific HER2-targeting mechanism, which activates multiple immune-mediated anti-tumor pathways including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). This multifaceted mechanism may help explain the broad clinical activity observed across diverse patient populations.
Potential New Standard of Care in HER2-Positive Gastroesophageal Cancer
The publication further strengthens the growing body of evidence supporting zanidatamab as a potentially transformative therapy in HER2-positive cancers. Safety analyses remained consistent with previously reported findings, with gastrointestinal events such as diarrhea generally occurring early in treatment, remaining manageable, and infrequently leading to treatment discontinuation.
Jazz Pharmaceuticals has submitted the HERIZON-GEA-01 data to the National Comprehensive Cancer Network (NCCN) for potential inclusion in future clinical practice guidelines. The company has also filed a supplemental Biologics License Application with the U.S. FDA for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, where the application is currently under Real-Time Oncology Review.
With robust Phase 3 evidence now published in one of medicine’s most prestigious journals, Ziihera is emerging as a leading HER2-targeted therapy capable of delivering unprecedented survival benefits in advanced gastroesophageal cancer. The findings represent a major advancement for precision oncology and offer new hope for patients facing a disease historically associated with poor long-term outcomes and limited therapeutic options.
Source: Jazz Pharmaceuticals press release
